Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025

Core Insights - Dynavax Technologies Corporation will report its third quarter 2025 financial results on November 5, 2025, after U.S. financial markets close [1] - A conference call and live audio webcast will be held on the same day at 4:30 p.m. ET/1:30 p.m. PT [1][2] Company Overview - Dynavax is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative vaccines to combat infectious diseases [3] - The company has two commercial products: HEPLISAV-B® vaccine, approved in the U.S., EU, and UK for hepatitis B prevention in adults aged 18 and older, and CpG 1018® adjuvant, used in HEPLISAV-B and various adjuvanted COVID-19 vaccines [3]